User Tools

Site Tools


indoximod

Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revision Previous revision
indoximod [2018/11/12 22:26]
administrador
indoximod [2018/11/12 22:27] (current)
administrador
Line 39: Line 39:
 Central PMCID: PMC5811356. Central PMCID: PMC5811356.
 )). )).
-Encouraged by these response data, the same regimen is now being tested in patients with diffuse intrinsic pontine glioma (DIPG), a dismal disease with no effective treatment option. Thus far, 3/6 patients enrolled are reported to have achieved good symptomatic and radiographic response.+Encouraged by these response data, the same regimen is now being tested in patients with diffuse intrinsic pontine glioma (DIPG), a dismal disease with no effective treatment option. Thus far, 3/6 patients enrolled are reported to have achieved good symptomatic and radiographic response 
 +((Fox E, Oliver T, Rowe M, Thomas S, Zakharia Y, Gilman PB, Muller AJ, 
 +Prendergast GC. Indoximod: An Immunometabolic Adjuvant That Empowers T Cell 
 +Activity in Cancer. Front Oncol. 2018 Sep 11;8:370. doi: 10.3389/​fonc.2018.00370. 
 +eCollection 2018. Review. PubMed PMID: 30254983; PubMed Central PMCID: 
 +PMC6141803. 
 +)).
indoximod.txt · Last modified: 2018/11/12 22:27 by administrador